移植共识解读2014年.pptVIP

报告人：许兰平 ;共识产生背景;根据疾病预后，选择供者，如：中危组可选择MSD或URD，高危组MSD或AD;ALL：成人再分年轻患者和中年以上患者，根据MRD情况，未明确供者类型 ;ALL：成人再分年轻患者和中年以上患者，根据MRD情况，未明确供者类型 ;Much progress has been made in unmanipulated haplo-HSCT ;Much progress has been made in unmanipulated haplo-HSCT ;Much progress has been made in unmanipulated haplo-HSCT ;Haplo-HSCT vs. chemotherapy for High-risk ALL ;Haplo-HSCT vs. chemotherapy Standard-risk Adult ALL;without any risk factors for relapse (n=59);P1: comparison among four groups; P2: comparison among chemo-low, HSCT-low and HSCT-high;Unmanipulated haplo-HSCT for patients with Ph（+） ALL ;Unmanipulated haplo-HSCT has similar therapeutic effect compared with HLA-identical sibling donor for patients with Ph（+） ALL ;共识要点及特点;恶性血液病 AML：APL、non-APL ALL：儿童、成人 CML MDS MF MM HL NHL 其他;AML- APL ;AML（非APL）年龄≤60 岁;AML（非APL）年龄≤60 岁;AML（非APL）年龄＞ 60 岁;ALL（年龄＞14 岁）;ALL （≤14 岁）;CML;MDS：;MF;NHL;MM;非恶性血液病-AA;非恶性血液病-地中海贫血;其他;-恶性血液病 清髓预处理方案 一般强度 加强强度 减低强度 ;供者选择：各种移植特点;供者选择的原则;;共识要点及特点;致谢（以医院首字母排序）